The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone

European Journal of Clinical Pharmacology

Volumn 54, Issue 9-10, 1998, Pages 761-766

  Lamberg, T S ^a   Kivisto K T ^a   Laitila, J ^a   Martensson K ^a   Neuvonen, P J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Buspirone; Fluvoxamine; Interaction

Indexed keywords

BUSPIRONE; FLUVOXAMINE; FLUVOXAMINE MALEATE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; BIOTRANSFORMATION; BUSPIRONE; CONTRACEPTIVES, ORAL, HORMONAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FLUVOXAMINE; HUMANS; MALE; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032438231     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050548     Document Type: Article

References (20)

1. 14C-buspirone HCl after intravenous and oral dosing in man (abstract). Clin Pharmacol Ther 37: 210
2. Goa KL, Ward A (1986) Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32: 114-129
3. Gammans RE, Mayol RF, LaBudde JA (1986) Metabolism and disposition of buspirone. Am J Med 80 [Suppl 3B]: 41-51
4. Jajoo HK, Mayol RF, LaBudde JA, Blair IA (1989) Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 17: 634-640
5. Jajoo HK, Blair IA, Klunk LJ, Mayol RF (1990) In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo. Xenobiotica 20: 779-786
6. Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ (1997) Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 62: 348-354
7. Lamberg TS, Kivistö KT, Neuvonen PJ (1998) Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther 63: 640-645
8. Joffe RT, Schuller DR (1993) An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 54: 269-271
9. Dominguez RA, Mestre SM (1994) Management of treatment-refractory obsessive compulsive disorder patients. J Clin Psychiatry 55 [Suppl]: 86-92
10. Fleishaker JC, Hulst LK (1994) A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46: 35-39
11. Gaillard Y, Gay-Montchamp JP, Ollagnier M (1993) Simultaneous screening and quantitation of alpidem, zolpidem, buspirone and benzodiazepines by dual-channel gas chromatography using electron capture and nitrogen-phosphorous detection after solid-phase extraction. J Chromatogr 622: 197-208
12. Van Der Meersch-Mougeot V, Diquet B (1991) Sensitive one-step extraction procedure for column liquid chromatographic determination of fluvoxamine in human and rat plasma. J Chromatogr 567: 441-449
13. Backman JT, Olkkola KT, Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59: 7-13
14. Anderson IM, Deakin JFW, Miller HEJ (1996) The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers. Psychopharmacology 128: 74-82
15. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45: 1211-1214
16. Wagner W, Vause EW (1995) Fluvoxamine. A review of global drug-drug interaction data. Clin Pharmacokinet 29 [Suppl 1]: 26-32
17. Buch AB, Van Harken DR, Seidehamel RJ, Barbhaiya RH (1993) A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. J Clin Pharmacol 33: 1104-1109
18. Barbhaiya RH, Shukla UA, Pfeffer M, Pittman KA, Shrotriya R, Laroudie C, Gammans RE (1994) Disposition kinetics of huspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur J Clin Pharmacol 46: 41-47
19. Jeppesen U, Rasmussen BB, Brosen K (1997) Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 62: 279-286
20. Spigset O, Adielsson G (1997) Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction. Int Clin Psychopharmacol 12: 61-63